-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10

Benzinga·05/16/2025 17:40:41
Listen to the news
Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $28 to $10.